RxDoctor Payments DataLook up a doctor →

Scott Arbaugh, MD

Psychiatry · Highland, ILNPI 1861553513

Payments from drug & device makers

$160,897in general payments, 2019–2025

Across 1,115 payments — averaging $144.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$122K
  • AbbVie$21K
  • Sunovion Pharmaceuticals Inc.$8K
  • Johnson & Johnson$2K
  • Lundbeck LLC$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • plus $6K from 29 others

What the payments were for

  • Consulting fees$1,9501%
  • Speaking & faculty fees$134,99884%
  • Travel & lodging$6,6894%
  • Food & beverage$17,17611%
  • Education$850%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$160,897 in reported general payments places this provider in the 95th percentile of 1,344 psychiatry providers in Illinois.

See all psychiatry providers in Illinois

Medicare billing

Part B allowed, 2024
$113,185
Medicare patients
394
Services billed
1,459

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl113$219,681
IngrezzaValbenazine Tosylate25$210,272
AustedoDeutetrabenazine13$169,158
RexultiBrexpiprazole118$160,496
CaplytaLumateperone Tosylate39$68,802
TrintellixVortioxetine Hydrobromide69$46,118
Venlafaxine Hcl ErVenlafaxine Hcl775$16,364
AuvelityDextromethorphan Hbr/Bupropion14$16,245
Duloxetine Hcl596$15,420
Oxcarbazepine112$9,915
Vilazodone Hcl95$9,912
Aripiprazole319$9,761
BelsomraSuvorexant18$9,574
Olanzapine382$9,533
Bupropion XlBupropion Hcl338$8,756

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$20,726$219,681113 claims
Neurocrine Biosciences, Inc.Ingrezza$643$210,27225 claims
Teva Pharmaceuticals USA, Inc.Austedo$85$169,15813 claims
Otsuka America Pharmaceutical, Inc.Rexulti$121,630$160,496118 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,214$68,80239 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$579$53,28587 claims
Axsome Therapeutics, Inc.Auvelity$493$16,24514 claims
MerckBelsomra$62$9,57418 claims
Lilly USA, LLCOlanzapine$18$9,533382 claims
Almatica Pharma LLCSertraline Hcl$30$8,155918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,344 psychiatry providers in Illinois.

Other psychiatry in Highland

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →